| 4.85 0.17 (3.63%) | 11-28 14:42 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.85 | 1-year : | 6.83 |
| Resists | First : | 5.01 | Second : | 5.85 |
| Pivot price | 4.32 |
|||
| Supports | First : | 4 | Second : | 3.38 |
| MAs | MA(5) : | 4.74 |
MA(20) : | 4.14 |
| MA(100) : | 5.48  |
MA(250) : | 6.53 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 85 |
D(3) : | 83.4 |
| RSI | RSI(14): 68 |
|||
| 52-week | High : | 9.64 | Low : | 2.54 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SPRY ] has closed below upper band by 22.9%. Bollinger Bands are 24.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.82 - 4.84 | 4.84 - 4.86 |
| Low: | 4.6 - 4.63 | 4.63 - 4.65 |
| Close: | 4.63 - 4.68 | 4.68 - 4.72 |
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Wed, 22 Nov 2023
2023-11-22 | NDAQ:SPRY | Press Release | ARS Pharmaceuticals Inc - Stockhouse Publishing
Thu, 09 Nov 2023
2023-11-09 | NDAQ:SPRY | Press Release | ARS Pharmaceuticals Inc - Stockhouse Publishing
Wed, 08 Nov 2023
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders ... - GlobeNewswire
Fri, 06 Oct 2023
ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray) - Yahoo Finance
Thu, 21 Sep 2023
ARS Pharmaceuticals (SPRY) Down on CRL for Nasal Spray - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 96 (M) |
| Held by Insiders | 3.758e+007 (%) |
| Held by Institutions | 34.7 (%) |
| Shares Short | 5,870 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.132e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -238 % |
| Return on Assets (ttm) | 936.6 % |
| Return on Equity (ttm) | -31.1 % |
| Qtrly Rev. Growth | 30000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -62 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 6.6e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|